WO2012168434A1 - Reprogrammation partielle de cellules somatiques en cellules souches tissulaires induites (its) - Google Patents

Reprogrammation partielle de cellules somatiques en cellules souches tissulaires induites (its) Download PDF

Info

Publication number
WO2012168434A1
WO2012168434A1 PCT/EP2012/060903 EP2012060903W WO2012168434A1 WO 2012168434 A1 WO2012168434 A1 WO 2012168434A1 EP 2012060903 W EP2012060903 W EP 2012060903W WO 2012168434 A1 WO2012168434 A1 WO 2012168434A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
somatic
induced tissue
partially reprogrammed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/060903
Other languages
English (en)
Inventor
Franck GRISCELLI
Annelise BENNACEUR-GRISCELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of WO2012168434A1 publication Critical patent/WO2012168434A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Definitions

  • the present invention provides a method for producing and expanding Induced Tissue Stem (iTS) cells from differentiated cells of neuroectodermic, endodermic and mesodermic lineages.
  • iTS Induced Tissue Stem
  • the body is made up of about 200 different kinds of specialised cells such as muscle cells, nerve cells, fat cells, live cells etc. All specialised cells originate form stem cells.
  • a stem cell is a cell that is not yet specialised and which has the capacity to self-renew and to give birth to a variety of different kinds of cells through a process called differentiation.
  • a stem cell that can become every type of cell in the organism is called pluripotent, whilst a stem cell that can become only certain types of cells is called multipotent.
  • Stem cells are found in the early embryo, the foetus, the placenta, umbilical cord, and in many different tissues of the adult body.
  • Stem cells are often divided into two groups: tissue specific stem cells (often referred to as adult stem cells) and pluripotent stem cells (including embryonic stem cells and induced pluripotent stem cells).
  • Tissue specific stem cells are undifferentiated cells found in foetal or adult tissues or organs. They are capable of self-renewal. Their differentiation is mainly restricted to forming the cell types of that tissue or organ. The chief role of tissue specific stem cells is to maintain and repair the tissue in which they are found.
  • adult stem cells probably contain adult stem cells.
  • the first adult stem cells were isolated from bone marrow and umbilical cord blood which contain relatively high numbers of stem cells.
  • adult stem cells were also isolated successfully from the brain, blood, muscle, skin, lung, pancreas and liver, although most tissues contain only a very small numbers of stem cells.
  • adult stem cells are used to produce new mature, differentiated cells in replacement of the cells that die in the natural process of ageing. They may also activated by disease or injury in order to repair the injured tissue.
  • tissue reconstruction it is desirable to produce large quantities of tissues stem cells for therapeutic application such as tissue reconstruction.
  • the inventors have developed a new generation of non-pluripotent stem cells called induced tissue stem cells.
  • the invention relates to a method for producing an induced tissue stem cell from a somatic cell comprising the steps of:
  • the invention also relates to a population of induced tissue stem cells obtainable by the method as described above.
  • the invention also relates to the use of a population of induced tissue stem cells as defined above for non-therapeutic purposes.
  • the invention also relates to a population of induced tissue stem cells as defined above for use in a method of treatment.
  • the invention relates to a method for producing an induced tissue stem cell from a somatic cell comprising the steps of:
  • LIF Leukemia Inhibitory Factor
  • the invention relates to a method for producing an induced tissue stem cell from a somatic cell comprising the steps of:
  • induced tissue stem cell or induced multipotent stem cell, or “partially reprogrammed cell” refers to a cell which has been reprogrammed, starting from a differentiated somatic cell, into a multipotent cell.
  • Said induced tissue stem (iTS) cell or induced multipotent (iMS) stem cell has the capacity, under different conditions, to differentiate into more than one differentiated cell type of the germ cell layer from which it originates.
  • iTS induced tissue stem
  • three main types of iTS or iMS can be produced: endodermic iTS, neuroectodermic iTS and mesodermic iTS.
  • an iTS obtained by partial reprogramming of a hepatocyte can be differentiated into hepatocytes, bile duct cells and pancreatic cells, all of which belong to the endodermic lineage.
  • the term "somatic cell” has its general meaning in the art. It refers to a diffentiated primary cell.
  • the somatic cell according to the invention can be from any mammalian species, with non-limiting examples including murine, bovine, simian, porcine, equine, ovine, or human cells.
  • said somatic cell is a mouse cell.
  • said somatic cell is a human cell.
  • Somatic cells can be isolated from any tissue, including, but not limited to, liver, heart, lung, skin, gut, intestine, muscle and spleen.
  • said somatic cell is selected from the group consisting of, epithelial, endothelial, neuronal, adipose, cardiac, skeletal muscle, immune cells, hepatic, splenic, lung, circulating blood cells, gastrointestinal, renal, and pancreatic cells.
  • said somatic cell is a hepatocyte.
  • the expression "feeder cell” refers to cells that serve as a basal layer for pluripotent stem cells and provide secreted factors, extracellular matrix, and cellular contacts for the maintenance of stem cells in the undifferentiated state without losing pluripotency.
  • Feeder cells can be inactivated by gamma irradiation or mitomycin.
  • the feeder fibroblasts may be from the group of fibroblasts, more particularly of human fibroblasts and more particularly of dermis fibroblasts, including dermis fibroblast cell lines. Examples of dermis fibroblast cell lines include but are not limited to CCD-1112SK (Hovatta O, et al.
  • dermis fibroblasts are previously treated to stop their proliferation before to be coated in the culture surface. Therefore, dermis fibroblasts may be irradiated or treated with a cell cycle blocking agent such as mitomycin.
  • the tern "dermis fibroblast” refers to a population of cells that synthesizes and maintains the extracellular matrix of dermis. Specific markers of dermis fibroblasts include vimentin and FAP (fibroblast activation protein).
  • said feeder cells are inactivated fibroblasts. Typically, when the somatic cell is a mouse cell, said feeder cells are mouse embryonic fibroblasts (MEF).
  • reprogramming factors reprogramming nuclear factor
  • reprogramming transcription factor reprogramming transcription factor
  • iPS induced pluripotent stem cells
  • reprogramming factors have been identified in document WO2007/069666. Reprogramming factors are described in Takahashi et al Cell 2006 126: 663-76; Takahashi et al. Cell 2007 131-861-72 and Yu et al. Science 2007 318 : 1917.
  • Reprogramming transcription factors can be of any mammalian origin. Typically, they can be of murine origin or of human origin. Preferably, the reprogramming transcription factors belong to the same species as the target cell which is to be reprogrammed. Examples of reprogramming factors include, but are not limited to:
  • Oct-3/4 is one of the family of octamer ("Oct") transcription factors, and plays a crucial role in maintaining pluripotency.
  • Oct octamer
  • Exemplary Oct3/4 proteins are the proteins encoded by the murine Oct3/4 gene (Genbank accession number NM_013633) and the human Oct3/4 gene (Genbank accession number NM_002701).
  • Sox2 The Sox family of genes is associated with maintaining pluripotency similar to Oct-3/4, although it is associated with multipotent and unipotent stem cells in contrast with Oct-3/4, which is exclusively expressed in pluripotent stem cells.
  • Sox2 was the initial gene used for induction (Takahashi et al Cell 2006 126: 663-76; Takahashi et al. Cell 2007 131-861-72; Yu et al. Science 2007 318 :1917)
  • Soxl yields iPS cells with a similar efficiency as Sox2, and genes Sox3, Soxl5, and Soxl8 also generate iPS cells.
  • sox-2 proteins are the proteins encoded by the murine Sox2 gene (Genbank accession number NM_011443) and the human Sox2 gene (Genbank accession number NM_003106).
  • Klf4 of the Klf family of genes was initially identified as a factor for the generation of mouse iPS cells and was also demonstrated to be a factor for generation of human iPS cells.
  • Exemplary Klf4 proteins are the proteins encoded by the murine klf4 gene (Genbank accession number NM_010637) and the human klf4 gene (Genbank accession number NM_004235).
  • Factors of the Myc family The Myc family of genes contains proto-oncogenes implicated in cancer, c-myc was shown to be a factor implicated in the generation of mouse iPS cells and of human iPS cells.
  • Exemplary c-myc proteins are the proteins encoded by the murine c-myc gene (Genbank accession number NM_010849) and the human c-myc gene (Genbank accession number NM_002467).
  • Nanog family In embryonic stem cells, Nanog, along with Oct-3/4 and Sox2, is necessary in promoting pluripotency.
  • LIN28 is an mRNA binding protein expressed in embryonic stem cells and embryonic carcinoma cells associated with differentiation and proliferation. Yu et al. demonstrated it is a factor in iPS generation, although it is not mandatory (Yu et al. Science 2007, vol318: 1917-20).
  • said reprogramming factor is selected from the group consisting of Oct-4, KLF4, sox2, and c-myc.
  • the reprogramming factor can be delivered to the somatic cell by any suitable technique known in the art.
  • the step of contacting a somatic cell with at least one reprogramming factor is performed by a non-integrating viral vector.
  • non-integrating viral vector refers to a viral vector that does not integrate into the host genome.
  • the expression of the gene delivered by the viral vector is temporary.
  • Non-integrating viral vectors suitable in the method of the invention include adenoviruses, adenovirus associated viruses, herpesviruses, baculoviruses, vaccinia viruses and Sendai virus.
  • non-integrating vectors are non-teratogenic.
  • chromosomal aberrations were identified in iPS cells produced by integrative vectors that may affect the differentiation capacity and increase the tumorigenicity of iPS cells.
  • the genetic abnormalities can arise at different stages of iPS cells generation.
  • aberrant DNA methylation of CG dinucleotides was observed in iPS cells that were linked to tumorigenicity.
  • These epigenetics changes were shown to contribute to neoplastic potential of iPS cells since cancer-related epigenetic abnormalities have been recently identified during reprogramming in iPS cells.
  • several aspects of the programming process remain poorly understood, especially in terms of recurrent genetic and epigenetic changes, suggesting that basic research efforts need to be performed in this field concomitant to permanent and rapid transfer to the biomedical applications.
  • iTS cells are produced without using integrative viral vectors and therefore do not have tumoral potential development, as demonstrated using the teratoma assay (see Example 2 below).
  • adenoviruses are used. These vectors have the advantage that they are easy to produce at high titers and have the capacity to efficiently transduce a wide range of post-mitotic cells.
  • Ad vectors are derived from Ad serotype 5, however, Ad vectors have also been generated from other serotypes, including human Ad2, Ad7, and Ad4 and non- human viruses.
  • the El and E3 genes were replaced with the transgene and are thus non-replicative and are propagated in cell lines that provide the El gene products in trans, such as the human 293 cell line. Combining the El and E3 deletions provides a total cloning capacity of 8.3 kb in one mutant virus.
  • the reprogramming factors can be delivered in a single virus using 2A "self-cleaving" peptides, which support efficient polycistronic expression from a single promoter or an internal ribosome entry site (IRES) sequence between two consecutive open reading frames.
  • 2A "self-cleaving" peptides which support efficient polycistronic expression from a single promoter or an internal ribosome entry site (IRES) sequence between two consecutive open reading frames.
  • Adenoviral vectors encoding up to two, three or four reprogramming factors can be used to generate iTS cells in both embryonic and adult somatic mouse and human cells.
  • the step of contacting the somatic cell with at least one reprogramming factor is typically performed by infection of somatic cells with non-integrating viral vectors encoding stem cell-associated genes into an adult, differentiated cell.
  • the multiplicity of infection (MOI) used for the reprogramming of the host cell is dependant on the cell type. It is therefore important to test a variety of MOI ranges for each cell type under the desired culture conditions in order to optimize the conditions of infection.
  • a non- integrating viral vector encoding the Green Fluorescence protein (GFP) is usually used and the efficiency of the infection is achieved after 96 hours by the quantification of GFP positive cells by flow cytometry.
  • the step of contacting the somatic cell with at least one reprogramming factor is performed by episomal vector or mRNA transfection. These techniques, like the non-integrating viral vectors, limit the risks of teratogenicity.
  • small molecules can be added during step a) in order to enhance reprogramming efficiency such as valproic acid, butyrate acid or ascorbic acid.
  • the method for producing iTS cells further comprises the step of selecting the partially reprogrammed cell for the absence of a stem cell marker.
  • the stem cell marker is SSEA1 for murine cells.
  • the stem cell marker is selected from the group consisting of SSEA3, SSEA4, TRA-1-60 and TRA-1-80 for human cells.
  • This negative selection step can be performed by any method known in the art. These methods include transcriptomic approaches such as Taqman Low Density Array (TLDA), and proteomic approaches, such as immunofluoresence, Western blot, ELISA or Fluorescence- Associated Cell Sorting (FACS).
  • transcriptomic approaches such as Taqman Low Density Array (TLDA)
  • proteomic approaches such as immunofluoresence, Western blot, ELISA or Fluorescence- Associated Cell Sorting (FACS).
  • murine cells are selected if they do not express SSEA1.
  • human cells are selected if they do not express TRAl-60.
  • human cells are selected if they do not express TRA1-81.
  • human cells are selected if they do not expressTRA-1-60 or TRA1-81.
  • the method can further comprise a step of selecting the partially reprogrammed cell for the presence of one or more foetal progenitor markers committed toward a specific lineage.
  • the expression “foetal progenitor markers committed toward a specific lineage” or “lineage-specific markers” refers to genes that are expressed by multipotent cells of a given lineage. According to the tissue from which the somatic cell was taken, said "lineage-specific markers" can be endodermic markers or neurectodermic markers or mesodermic markers.
  • endodermic markers include, but are not limited to, Foxa2, Gata4, Afp, Soxl7, CER, CXCR4 and Fnl.
  • neurectodermic markers include, but are not limited to, Soxl, Sox2, Sox3.
  • mesodermic markers include, but are not limited to, brachyury and flkl .
  • the method further comprises the step of selecting the partially reprogrammed cell for the absence of markers of differentiated mature cells.
  • markers of differentiated mature cells can be markers of the somatic cell from which the partially reprogrammed cell was obtained.
  • the partially reprogrammed cell can be selected for the absence of alpha-anti-trypsin and/or albumine.
  • the invention also relates to a substantially pure population of induced tissue stem cells obtainable by the method as described above.
  • substantially pure homogenous population refers to a population of cells wherein the majority (e.g., at least about 80%, preferably at least about 90%, more preferably at least about 95%) of the total number of cells have the specified characteristics of the iTS of interest.
  • isolated refers to a cell or a population of cells which has been separated from at least some components of its natural environment.
  • the somatic cell is patient-specific.
  • the method of the invention can be used to generate patient-specific iTS cells.
  • iTS cells can be obtained from patients affected with monogenic and multigenic diseases or inherited and acquired diseases such as Fanconi anemia (Raya et al. Nature 2009, 460: 53-59); adenosine desaminase immune deficit (ADA-SCID), Gaucher' s disease, muscular dystrophy, Parkinson's disease, Huntington's disease, Alzheimer, Wilson disease, hemochromatosis and iron overload disorders, alpha-one antitrypsin and ornithine carbamoyl transferase deficiencies, type 1 or type 2 diabetes and cancer.
  • Fanconi anemia Raya et al. Nature 2009, 460: 53-59
  • ADA-SCID adenosine desaminase immune deficit
  • Gaucher' s disease muscular dystrophy
  • Parkinson's disease Huntington's disease
  • Alzheimer Wilson disease
  • hemochromatosis and iron overload disorders alpha-one antitrypsin and ornithine carbamoyl transferase deficiencies
  • Patient- specific iTS cells represent a valuable model to study diseases. Moreover they are of great interest in regenerative therapy, since they represent a potentially unlimited source of autogenic cells that can be expanded and further re- differentiated into any given tissue.
  • the method of the present invention leads to the production of large amounts of multipotent cells which can then be differentiated into a number of different cell types.
  • ES embryonic stem
  • iPS induced pluripotent stem
  • ES cells are pluripotent stem cells derived from the inner cell mass of embryos at the blastocyst stage. They are a valuable tool for the study of developmental processes and represent a potentially unlimited source of material for tissue regeneration. However, their use raises ethical issues which are still not resolved.
  • iPS cells are similar to embryonic stem (ES) cells, and open new ways for the study of developmental processes, the modeling of human diseases and for the design of regenerative medical strategies including drug testing.
  • iPS cells are functionally and molecularly highly similar to ES cells and share similar cell surface markers. Like ES cells, iPS cells produce and express on their cell surface one or more of the following cell surface antigens: SSEA-3, SSEA-4, TRA-1-60, TRA- 1-81, alkaline phosphatase, SCA-1, hTERT and Nanog.
  • iPS cells in contrast to ES cells, the benefits of iPS cells could be jeopardized by safety concerns such as their tumorigenicity for several reasons:
  • iPS cells produced by integrative vectors that may affect the differentiation capacity and increase the tumorigenicity of iPS cells.
  • the genetic abnormalities can arise at different stages of iPS cells generation.
  • the population of iTS cells according to the invention may be suitable for a variety of both non-therapeutic and therapeutic applications.
  • the inventors have found that, unexpectedly, it was possible to obtain partially reprogrammed cells from somatic cells, using the same reprogramming factors as those used for obtaining induced pluripotent stem cells. Further, they have discovered that this partially reprogrammed state corresponds to a dedifferentiated multipotent and foetal state, where the cells are capable of differentiating into several cell types of a given lineage.
  • this partially reprogrammed state is an intermediate stage in the reprogramming phenomenon which brings the cells back to a multipotent, self renewing state that had never been identified in the prior art.
  • the step of isolating said partially reprogrammed cells enables to "capture" the cells in a partially reprogrammed state, rather than carrying out the reprogramming all the way back to pluripotent state.
  • the differentiation of iTS to specific lineages is less time consuming and costly compared to the multiple steps used for the differentiation of iPS cells that are cumbersome and costly.
  • the iTS-derived cells are produced with higher purity. Therefore, the method according to the present invention represents an easy way to produce tissue specific stem cells and their derived lineages for drug and toxicity assays, and for further therapeutic applications.
  • the invention also relates to the use of a substantially pure population of iTS cells as defined above for non-therapeutic methods, such as patient-specific disease modelling, study of molecular mechanisms underlying the pathogenesis, drug screening, predictive toxicity testing.
  • said non-therapeutic methods can include screening methods for compounds that are involved in differentiation pathways.
  • Tissue specific precursor cell lines have been described in the art.
  • D2 discloses a mouse pancreatic stem cell line, HN-5, and a human cell line PANC-1. These cell lines are epithelial carcinoma derived from human and mouse pancreas respectively, which are therefore immortalized. They have major genetic perturbations with 63 chromosomes.
  • iTS cells according to the invention are not immortalized cells but have the property of self -renewal since: 1) they highly express the receptor of leukemia inhibitory factor (LIF).
  • LIF leukemia inhibitory factor
  • the LIF is preferably added daily to the growth medium allowing iTS cells in vitro to continue proliferating without differentiating.
  • iTS latent transcription factor STAT3, a necessary event in vitro for the continued proliferation of mouse iTS.
  • LIF latent transcription factor
  • iTS cells As embryonic stem cells, when cultured in the absence of LIF, iTS cells differentiate spontaneously, forming three-dimensional (3D) aggregates called embryoid bodies. 3) As embryonic stem cells, iTS can proliferate and differentiate spontaneously in vivo when injected intra- muscularly into NOD/SCID mice. However, in contrast to embryonic stem cells, iTS cells according to the present invention are not pluripotent. Their differentiation into somatic cells is faster.
  • iTS cells according to the present invention can be distinguished from somatic cells (fully differentiated cells) on the one hand, and from iPS cells (fully undifferentiated) on the other hand.
  • the invention also relates to a pharmaceutical composition comprising a substantially pure population of iTS cells as defined above and optionally a pharmaceutically acceptable carrier or excipient.
  • the term "pharmaceutically acceptable carrier or excipient” refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the progenitor cells, and which is not excessively toxic to the host at the concentrations at which it is administered.
  • suitable pharmaceutically acceptable carriers or excipients include, but are not limited to, water, salt solution (e.g., Ringer's solution), oils, gelatines, carbohydrates (e.g., lactose, amylase or starch), fatty acid esters, hydroxymethylcellulose, and polyvinyl pyroline.
  • Pharmaceutical compositions may be formulated as liquids, semi-liquids (e.g., gels) or solids (e.g., matrix, lattices, scaffolds, and the like).
  • the invention also relates to a substantially pure population of iTS cells as defined above or to a pharmaceutical composition as defined above for use in a method of treatment.
  • the invention also relates to a method for treating a subject comprising the step of administering to said subject an efficient amount of a substantially pure population of iTS cells as defined above.
  • the term "subject” refers to a mammal, preferably a human being, that can suffer from pathology associated with skin damage, but may or may not have the pathology.
  • the term “treating” or “treatment”, as used herein refers to a method that is aimed at delaying or preventing the onset of a pathology, at reversing, alleviating, inhibiting, slowing down or stopping the progression, aggravation or deterioration of the symptoms of the pathology, at bringing about ameliorations of the symptoms of the pathology, and/or at curing the pathology.
  • the population of partially reprogrammed cells or induced pluripotent cells of the invention can be used in order to produce large amounts of a given cell type, by differentiation under suitable conditions. This differentiation is less time-consuming and leads to iTS-derived somatic cells with a high purity, compared to those obtained by differentiating iPS cells or ES cells.
  • the invention relates to a method for amplifying a somatic cell comprising the steps consisting of:
  • LIF Leukemia Inhibitory Factor
  • the method of the invention can be used as a method for obtaining a population of substantially pure, fully differentiated cells, by selecting the suitable factors in step e).
  • the method can be used for obtaining hepatocytes, which express albumin, liver enzymes systems such as proteins of the cytochrome P450 superfamily. In another embodiment the method can be used for obtaining insulin-producing pancreatic beta cells.
  • Figure 1 Histological (A) and molecular (B) analysis of endodermc-derived iTS cells
  • Figure 2 Molecular signature of endodermic iTS in comparison with murine hepatocytes
  • FIG. 3 Spontaneous differentiation of iTS cells into hepatocytes expressing albumin mRNA for 5 different subclones.
  • iTS cells from mouse hepatocytes was attempted using an adenovirus vector, which allows transient and high level expression of exogenous genes without integrating into the host genome.
  • adenovirus vector which allows transient and high level expression of exogenous genes without integrating into the host genome.
  • cDNAs of Oct4, Sox2, cMyc and Klf4 were introduced into non-replicative adenoviral vectors deleted of El and E3 under the control of the hCMV immediate early promoter.
  • Hepatocytes are highly permissive for adenoviral infection and 20 MOI (multiplicity of infection or number of virus per cell) of adenovirus encoding GFP led to an infection efficiency of 100% of cells expressing GFP. The dose of 20 MOI was thus used to infect adult murine hepatocytes.
  • Adherent liver cultures were established from 6 to 8 week old mice. Briefly, the liver was isolated and a catheter was inserted into the vena cava and maintained using clamps. The liver was washed with 50 ml of 0.5mM EGTA HEPES buffer and then perfused with the HEPES/CaC12/Collagenase buffer. Once the perfusion was completed, the clamps were removed and the liver excised and placed in a 10 cm Petri dish with 20 ml of chilled William's medium containing 10% serum and antibiotic. The liver was then cut in several locations and the dispersed cells were filtered through a 40 ⁇ cell strainer.
  • the cells were then re-suspended in warm William's medium containing 0.5 mg/ml of bovine serum albumin , lx Insulin-Transferrin- Selenium, and 10 " M dexamethasone on collagen I-treated petri dish of 10 cm.
  • Approximately one million hepatocytes were infected with 20 MOI of adenovirus encoding Oct4, Sox2, cMyc and Klf4 and after 5 days of infections, cells were manually pooled and plated on mitomycin C-arrested Mouse Embryonic fibroblasts (MEF) in daily changed ES cell culture medium; DMEM medium supplemented with specific cytokines, in particular Leukemia Inhibitory Factor (LIF).
  • MEF Mouse Embryonic fibroblasts
  • Murine somatic cells were supplemented with 15% SVF, 1% Non-Essential Amino Acids, lx Penicillin-Streptomycin, 100 ⁇ ⁇ -mercaptoethanol and 1000 U/ml of LIF. After 10 to 20 days, colonies appeared and were picked and cultured in MEF-free conditions on collagen I-treated plates in ES cell culture medium. In this manner, more than 50 colonies have been isolated. For two of them (clones 3 and 6), single cells were added in a 96-well cell culture plate for subcloning. After 1 to 2 weeks of culture each subclone (6.1 to 6.8 and 3.1 and 3.14) was scraped and plated onto collagen-coated 12 well microtiter plates and expanded. Each clone and subclone was called an endodermic iTS cell and further characterized by the following techniques. Flow cytometry
  • TLDA Human Stem Cell Pluripotency Array
  • the micro-fluidic card (Applied Biosystems, Foster City, CA, USA) consisted of 4 identical sets of 96 genes (90 target genes and six endogenous controls). Target genes included genes expressed in undifferentiated cells, genes involved in the maintenance of pluripotency, sternness- related genes and differentiation marker genes. Quantitative PCR was carried out with the ABI PRISM 7900HT Sequence Detection System. Clustering gene expression patterns were determined using hierarchical algorithms of StatMiner software. In the present study, Euclidean distance and complete linkage methods were applied even though clustering results were identical whatever the linkage method and distance measure used.
  • TDLA TDLA we first noted a very different hierarchical clustering of pluripotent gene expression and differentiation genes in different endodermic iTS cells in comparison to murine ES cells (mES D3) and hepatocytes of origin.
  • -Endodermic iTS cells do not express by TLDA, ectodermic and mesodermic markers. -Endodermic iTS cells express by TLDA: Foxa2, Gata4, Afp and Fnl mRNAs involved in visceral and parietal endoderm and liver development.
  • Iapp Islet amyloid polypeptide
  • pancreas beta cells express by TLDA, Iapp mRNAs.
  • Iapp Islet amyloid polypeptide
  • pancreas beta cells that was shown to be colocalized with insulin and glucagon in fetal and adult pancreatic islet cells.
  • Clones 3 and 6 showed polymorphic cells with one or two nucleus, whereas subclones were monomorphic and mononuclear cells with a high nuclear-to-cytoplasmic ratio, which typically characterizes undifferentiated and stem cells as opposed to differentiated cells.
  • Transmission electron microscopy of all clones and subclones analyzed, showed the presence of fusiform cells with membranes showing numerous villosities.
  • the nucleus showed an abundant euchromatin denoting that, in contrast to hepatocytes, iTS cells are transcriptionally active cells.
  • the cytoplasm showed numerous mitochondria undergoing fusion or division as well as very rare lipidic structures, granular and agranular endoplasmic reticulum and golgi apparatus.
  • endodermic iTS cells are tripotent progenitor cells since they express specific markers that can be fated to definitive endoderm bile duct cells, hepatocytes and to pancreatic cells.
  • endodermic iTS cells were shown to express by RT-PCR:
  • liver progenitor cells such as Cytokeratin (CK) 8 and CK18, Hepatocytes nuclear factor 4 alpha (HNF4a) and alpha- fetoprotein (AFP).
  • CK Cytokeratin
  • HNF4a Hepatocytes nuclear factor 4 alpha
  • AFP alpha- fetoprotein
  • HNF6 Hepatocytes nuclear factor 6
  • HNFla Hepatocytes nuclear factor 1 alpha
  • HNFlb Hepatocytes nuclear factor 1 beta
  • pancreatic progenitor cells such as: Pdxl, Pax4, Pax6, Neurogenin 3 (Ngn3), HFN6, and HNFla. Production of hepatocyte-like cells from murine endodermic iTS cells producing albumin.
  • endodermic iTS cells negative for albumin at transcriptional levels can be differentiated into hepatocyte-like cells producing high levels of liver-specific markers.
  • Endodermic iTS cells were maintained in monolayers cultured on plates coated or not with collagene in mES culture media under standard conditions (37°C; 5%C0 2 /ambient 0 2 ).
  • hepatocyte culture medium consisting of William's medium containing lx Insulin-Transferrin-Selenium, 10 " M dexamethasone and 20 ng/ml of Oncostatin M, an interleukin-6 family cytokine that was initially found to induce maturation of fetal hepatic cells derived from embryonic day 14.5 liver in vitro. After five days of culture under these conditions, the cells were found to express high levels of albumin. An average of 52% of cells were albumin-positive based on flow cytometry analysis. After completion of the protocol, the cells were also found to display several known hepatic functions. Periodic acid-Schiff (PAS) staining indicated glycogen synthesis by the differentiated cells and red O staining identified the presence of lipid droplets.
  • PAS Periodic acid-Schiff
  • pancreatic-like cells Production of pancreatic-like cells from murine endodermic iTS cells producing Insulin.
  • pancreatic progenitors such as Pdxl, Pax4, Ngn3, HFN6, and HNFla
  • endodermic iTS cells generated from differentiated hepatocytes can give rise to pancreatic-like cells capable of generating insulin.
  • pancreatic progenitors such as Pdxl, Pax4, Ngn3, HFN6, and HNFla
  • endodermic iTS cells generated from differentiated hepatocytes can give rise to pancreatic-like cells capable of generating insulin.
  • pancreatic progenitors such as Pdxl, Pax4, Ngn3, HFN6, and HNFla
  • ITS cells were harvested by trypsinization and injected intramuscularly into the flanks of NOD/SCID mice, using ⁇ 5 millions cell per injection. Mice were sacrificed 3 months later and teratomas were isolated and processed for histological analysis. Three clones and sub-clones were injected showing two kinds of tissues: a tissue with an architecture of the hepatic parenchyma with cells expressing albumin and a tissue with bile duct structure positive for glycogen, for acid mucosubstances after PAS and Alcian blue staining respectively and for EA1/EA3 cytokeratin.
  • endodermic iTS cells In order to document the potential of endodermic iTS cells to colonize tissues of endodermic origin, endodermic iTS cells were injected in the pancreas and in the spleen of partially hepatectomized mice. For these experiments, endodermic iTS cells were infected with a retrovirus encoding the luciferase gene and we used a firefly bioluminescence system for a weekly detection of the graft cells. We showed that all endodermic iTS cells tested have the potential to be grafted into the pancreas over a period of 56 days. Furthermore all endodermic iTS cells have the potential to recolonize the liver of the mice over a period of 35 days.
  • iTS cells induced tissue stem cells
  • Example 2 Non-oncogenicity of iTS cells
  • the in vivo teratoma model described above also provides an accessible system for the evaluation of the oncogenicity of the cells.
  • the inventors have shown that the injection of endodermal iTS cells as described above, leads to a complete absence of ectodermal and mesodermal tissues and the absence of malignant tissues.
  • Two kinds of tissues were observed by histological analysis: a tissue with an apparent architecture of a heaptic parenchyma with cells expressing albumin, and a tissue with bile duct structure (Figure 1A).
  • RT-PCR analysis of these tissues revealed the presence of albumin and G6P mRNA, that were absent in the original iTS cells ( Figure IB).
  • TLDA Human Stem Cell Pluripotency Array
  • TDLA analysis showed very different gene-expression patterns between endodermic iTS cells and hepatocytes (see Figure 2A) and molecular signature has been established for endodermic iTS cells in comparison to hepatocytes of origin (see Figure 2B).
  • Example 4 Spontaneous differentiation of iTS cells upon removal of LIF
  • Human iPS and ES cells can adopt a hepatic cell fate in vitro by using a cocktail of different specific factors: Activin A, BMP-4, FGF-2, HGH and oncostatin M.
  • Activin A Activin A
  • BMP-4 BMP-4
  • FGF-2 FGF-2
  • HGH HGH
  • oncostatin M oncostatin M.
  • iTS cells are able to differentiate spontaneously to albumin producing hepatocytes cells when LIF are removed from the growth medium. Five subclones have been tested with and without LIF and we were able to show that albumin transcripts and protein are produced without LIF (see Figure 3).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention concerne un procédé de production et d'expansion de cellules souches tissulaires induites (iTS) à partir de cellules différenciées de lignées neuroectodermiques, endodermiques et mésodermiques.
PCT/EP2012/060903 2011-06-08 2012-06-08 Reprogrammation partielle de cellules somatiques en cellules souches tissulaires induites (its) Ceased WO2012168434A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305706.1 2011-06-08
EP11305706 2011-06-08

Publications (1)

Publication Number Publication Date
WO2012168434A1 true WO2012168434A1 (fr) 2012-12-13

Family

ID=46354193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/060903 Ceased WO2012168434A1 (fr) 2011-06-08 2012-06-08 Reprogrammation partielle de cellules somatiques en cellules souches tissulaires induites (its)

Country Status (1)

Country Link
WO (1) WO2012168434A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152321A1 (fr) * 2013-03-15 2014-09-25 The Jackson Laboratory Isolement de cellules souches non embryonnaires et leurs utilisations
JP2020089313A (ja) * 2018-12-06 2020-06-11 国立大学法人 琉球大学 ヒト組織特異的幹／前駆細胞の人工作製方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069666A1 (fr) 2005-12-13 2007-06-21 Kyoto University Facteur de reprogrammation nucleaire
WO2009126927A2 (fr) * 2008-04-11 2009-10-15 Joslin Diabetes Center, Inc. Procédés de génération de cellules produisant de l'insuline
WO2010075575A1 (fr) * 2008-12-23 2010-07-01 Biopips, Inc. Compositions et procédés de reprogrammation cellulaire sans modification génétique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069666A1 (fr) 2005-12-13 2007-06-21 Kyoto University Facteur de reprogrammation nucleaire
WO2009126927A2 (fr) * 2008-04-11 2009-10-15 Joslin Diabetes Center, Inc. Procédés de génération de cellules produisant de l'insuline
WO2010075575A1 (fr) * 2008-12-23 2010-07-01 Biopips, Inc. Compositions et procédés de reprogrammation cellulaire sans modification génétique

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BLYSZCZUK P ET AL: "Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, vol. 100, no. 3, 4 February 2003 (2003-02-04), pages 998 - 1003, XP002233762, ISSN: 0027-8424, DOI: 10.1073/PNAS.0237371100 *
COLMAN A: "Making new beta cells from stem cells", SEMINARS IN CELL AND DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, GB, vol. 15, no. 3, 1 June 2004 (2004-06-01), pages 337 - 345, XP002365752, ISSN: 1084-9521, DOI: 10.1016/J.SEMCDB.2004.02.003 *
NOGUCHI HIROFUMI ET AL: "Induction of pancreatic stem/progenitor cells into insulin-producing cells by adenoviral-mediated gene transfer technology", CELL TRANSPLANTATION, US, vol. 15, no. 10, 1 January 2006 (2006-01-01), pages 929 - 938, XP009122625, ISSN: 0963-6897, DOI: 10.3727/000000006783981431 *
RAYA ET AL., NATURE, vol. 460, 2009, pages 53 - 59
SANDT ET AL., PLOS ONE, vol. 7, 2012, pages L-7
TAKAHASHI ET AL., CELL, 2007, pages 131 - 861,72
TAKAHASHI ET AL., CELL, vol. 126, 2006, pages 663 - 76
TATEISHI KEISUKE ET AL: "Generation of insulin-secreting islet-like clusters from human skin fibroblasts", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 283, no. 46, 14 November 2008 (2008-11-14), pages 31601 - 31607, XP009147429, ISSN: 0021-9258, [retrieved on 20080909], DOI: 10.1074/JBC.M806597200 *
YU ET AL., SCIENCE, vol. 1318, 2007, pages 1917 - 20
YU ET AL., SCIENCE, vol. 318, 2007, pages 1917

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152321A1 (fr) * 2013-03-15 2014-09-25 The Jackson Laboratory Isolement de cellules souches non embryonnaires et leurs utilisations
JP2016513469A (ja) * 2013-03-15 2016-05-16 ザ ジャクソン ラボラトリー 非胚性幹細胞の単離とその使用
JP2020089313A (ja) * 2018-12-06 2020-06-11 国立大学法人 琉球大学 ヒト組織特異的幹／前駆細胞の人工作製方法
JP7389980B2 (ja) 2018-12-06 2023-12-01 国立大学法人 琉球大学 ヒト膵臓組織特異的幹／前駆細胞の人工作製方法

Similar Documents

Publication Publication Date Title
EP3019596B1 (fr) Compositions et procédés de reprogrammation de cellules non-pluripotentes en cellules souches pluripotentes
Liu et al. Generation of endoderm‐derived human induced pluripotent stem cells from primary hepatocytes
Marcus et al. Fetal stem cells from extra‐embryonic tissues: do not discard
US9926532B2 (en) Method of generating induced pluripotent stem cells and differentiated cells
Rony et al. Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming
US9777258B2 (en) Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the method, and methods for using the cells
EP2090649A1 (fr) Procédé de reprogrammation de cellules différentiées
CN102725399B (zh) 制备多能干细胞的材料和方法
Lewandowski et al. Techniques of human embryonic stem cell and induced pluripotent stem cell derivation
Saito et al. Human amnion–derived cells as a reliable source of stem cells
CN113015794A (zh) 包含用于条件性永生化的可控转基因的诱导多能细胞
CN108779435B (zh) 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
Li et al. Generation of functional hepatocytes from mouse induced pluripotent stem cells
Moraveji et al. Inhibition of glycogen synthase kinase-3 promotes efficient derivation of pluripotent stem cells from neonatal mouse testis
Chiang et al. Induced pluripotent stem cells and hepatic differentiation
WO2012168434A1 (fr) Reprogrammation partielle de cellules somatiques en cellules souches tissulaires induites (its)
Al Abbar et al. Generation of induced pluripotent stem cells by a polycistronic lentiviral vector in feeder-and serum-free defined culture
Pathak et al. Stem cells and aging
Petzendorfer et al. Induced pluripotent stem cells derived from amniotic fluid stem cells
Spinelli et al. Principles of stem cell biology
KR20160126734A (ko) 자가면역질환 환자 특이적 유도만능줄기세포의 제조방법 및 이의 이용
Palecek Derivation and Expansion of Human Pluripotent Stem Cells
Xu et al. Induced Pluripotent Stem Cells: Proliferation, Migration, MicroRNA, Signaling Molecules
Marongiu et al. Amniotic epithelial stem cells in regenerative medicine
Alviano et al. Cell Populations Isolated from Amnion, Chorion, and Wharton’s Jelly of Human Placenta

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12729420

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12729420

Country of ref document: EP

Kind code of ref document: A1